This brief publication discusses current standards for the initial evaluation of newly diagnosed, advanced NSCLC; recommended first-line therapy for advanced NSCLC; and requirements and recommendations for biomarker analysis to guide treatment planning and initiation in affected patients.
Thomas Eldridge Stinchcombe, MD
Professor of Medicine
Division of Medical Oncology
Duke University School of Medicine